



**LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
Pharmacy Affairs**

September 14th, 2020

TO: MHLA Clinics
FROM: DHS Pharmacy Affairs
RE: DHS MHLA Formulary Update

MY HEALTH LA FORMULARY

Due to recent distribution restrictions placed by Eli Lilly on MHLA formulary products, Humalog® vial and Humalog KwikPen®, access will be limited. **The temporary formulary amendments outlined below will go into effect immediately.** We are working on a longer term solution. We appreciate your efforts to ensure MHLA participants' continuity of care and strongly encourage MHLA Clinics to proactively work with your 340B contract pharmacies as we navigate through these manufacturer-mandated 340B distribution restrictions.

UPDATE – Temporary Formulary Amendment (effective September 14th, 2020)

Drug Product	Comments
Humalog® vial and Humalog KwikPen® 100 Units/mL	<p>Humalog® vial and Humalog KwikPen® claims will temporarily <u>reject for contract 340B pharmacies</u> with the message “Contact the CCT at 855-444-7757 for guidance.”</p> <p>If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:</p> <ul style="list-style-type: none"> • <u>Has an On-Site Pharmacy or Dispensary:</u> CCT will advise you to direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy or dispensary, please contact the prescriber for alternative formulary options, <u>including temporary formulary allowance for Novolog® vial and Novolog FlexPen®.</u> • <u>Does NOT have an On-site Pharmacy or Dispensary:</u> CCT will advise you to contact the prescriber for alternative formulary options, <u>including temporary formulary allowance for Novolog® vial and Novolog FlexPen®.</u> <p><u>NOTE:</u> Eli Lilly's distribution restrictions does NOT apply to On-Site Pharmacies and Dispensaries. Humalog® vial and Humalog KwikPen® will continue to process according to prior formulary restrictions at these locations.</p>

This document contains confidential information intended for MHLA Program Healthcare Providers and Professionals. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.